Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07275970 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD
A Phase 1 study of PTSD, sponsored by Suzanne "Sue" Sisley MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07275970: Recruiting Phase 1 study of PTSD, sponsored by Suzanne "Sue" Sisley MD.
NCT07275970 is a Phase 1 study of PTSD that is actively recruiting participants, run by Suzanne "Sue" Sisley MD. The registered enrollment target is 24 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07275970, a Phase 1 study of PTSD, is actively recruiting participants, sponsored by Suzanne "Sue" Sisley MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.
Conditions Studied
Interventions
- DRUG Psychedelic
Study Locations (1)
Arizona
- Scottsdale Research Institute - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT07275970 shows while recruiting
NCT07275970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (92% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which Psychedelic is the first listed.
NCT07275970 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07275970 about?
NCT07275970 is a clinical study titled "Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD". This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.
What is the current status of trial NCT07275970?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-02-09. Estimated completion is 2026-03.
What conditions does trial NCT07275970 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT07275970?
The interventions under investigation include: Psychedelic (DRUG).
Who is sponsoring clinical trial NCT07275970?
This trial is sponsored by Suzanne "Sue" Sisley MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07275970 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07275970's enrollment target sits among peer trials
24 136th of 154 higher than 18 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Psilocybin Study in Transdiagnostic Population
RECRUITING · Phase 1
-
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
ACTIVE NOT RECRUITING · Phase 1
-
Methylphenidate for Ptsd and Stroke Veterans
COMPLETED · Phase 1
-
Doxazosin FOR Ptsd
COMPLETED · Phase 1
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI